

AstraZeneca Hits U.K. Antitrust Review with \$39B Alexion Buy After U.S. FTC Clearance

PUBLICATIONS | LESS THAN 1 MIN READ


May 25, 2021

By: Angus Liu
FiercePharma

Axinn partner Jeny Maier's commentary was included in the *FiercePharma* article, "AstraZeneca Hits U.K. Antitrust Review with \$39B Alexion Buy After U.S. FTC Clearance."

Click [here](#) to access the article.

Related People



Jeny M. Maier

Related Services

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
AXINN VIEWPOINTS LITIGATION & TRIALS

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved